#mrna-lnp-therapy

#mrna-lnp-therapy

Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.

GPT-Rosalind is designed to support evidence synthesis, hypothesis generation, experimental planning, and multi-step scientific workflows across biochemistry, genomics, and protein engineering.

Amazon Bio Discovery enables scientists to run complex computational workflows through more than 40 AI-specialized foundational models, trained on a wide range of biological datasets. These models generate and evaluate potential drug molecules, alongside AI agents that help scientists to select models, optimize inputs and evaluate candidates according to their research.

mRNA vaccines have demonstrated their ability to prevent approximately eight million COVID infections within the first six months of their rollout, showcasing their effectiveness in combating the pandemic.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, stated Shai Novik, Executive Chairman of Enlivex.

Antibiotics are essential for modern medicine, but bacteria are evolving and developing resistance, turning routine infections into life-threatening conditions. A global analysis estimates that antibiotic-resistant infections could cause over 39 million deaths by 2050.

The settlement resolves all U.S. and international patent litigation concerning the unauthorized use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in Moderna's COVID-19 vaccines. The agreement came just days before a highly anticipated jury trial was scheduled to begin in the U.S. District Court for the District of Delaware.

Today represents the first real acknowledgement that team and those scientists have gotten that their technology was instrumental in Covid-19 vaccines, or at least the Moderna vaccine as we're announcing today with this settlement. This settlement validates the scientific contributions made by the researchers at Arbutus and Genevant in developing the lipid nanoparticle delivery system.

Before treatment began, participants underwent neuroimaging. Instead of relying on a single modality, the researchers fused structural connectivity (how regions are physically wired) with functional connectivity (how regions co-activate at rest). The goal was not to throw every possible feature at a black box, but to learn a constrained pattern-what the authors call structure-function "covariation"-that carries the most predictive signal for outcome. In other words, the model tries to find the smallest set of connections that meaningfully forecasts symptom change.

I went to ChatGPT and came up with a plan on how to do this. He also used AlphaFold, an AI tool from Google's DeepMind, to find mutated proteins that could be potential targets for treatment. While an immunotherapy treatment that looked like a good fit for Rosie was identified, the drugmaker wouldn't provide it.

The news is the latest sign of the FDA's heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr., particularly those using mRNA technology, which he has criticized before and after becoming the nation's top health official. Moderna received what's called a "refusal-to-file" letter from the FDA that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.

Now, researchers have created an artificial-intelligence system that vastly simplifies and accelerates the process of chemical synthesis. The system, which is called MOSAIC and is described in a study published in Nature on 19 January, recommended conditions that researchers were able to use to generate 35 compounds with the potential to become products like pharmaceuticals, agrochemicals or cosmetics without needing to do any further trawling or tweaking.

When mitochondria are exposed to tissue or blood, they lose the electrical gradient across their outer membrane. Mitochondria that lack such a gradient are recognized by a cell's internal machinery as damaged and quickly destroyed. The vast majority of previous studies involved injecting 'naked' mitochondria directly into the bloodstream or tissue sites, but the approach isn't very efficient, so researchers often have to use 'ridiculous' doses of mitochondria.

X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.

We knew that if you inject these nanoparticles into an animal model, the nanoparticles get taken up by antigen presenting cells and this resulted in increased regulatory T-cells and decreased inflammatory disease. However, we did not know how this happens,

While the move came as a surprise to the high-profile vaccine maker, it is just the latest hostility toward vaccines-and mRNA vaccines in particular-from an agency overseen by the fervent anti-vaccine activist Robert F. Kennedy Jr. In his first year in office, Kennedy has already dramatically slashed childhood vaccine recommendations and canceled $500 million in research funding for mRNA vaccines against potential pandemic threats.

Martschenko's argument is largely that genetic research and data have almost always been used thus far as a justification to further entrench extant social inequalities. But we know the solutions to many of the injustices in our world-trying to lift people out of poverty, for example-and we certainly don't need more genetic research to implement them. Trejo's point is largely that more information is generally better than less.

Scientists in the laboratory of Rendong Yang, PhD, associate professor of Urology, have developed a new large language model that can interpret transcriptomic data in cancer cell lines more accurately than conventional approaches, as detailed in a recent study published in Nature Communications. Long-read RNA sequencing technologies have transformed transcriptomics research by detecting complex RNA splicing and gene fusion events that have often been missed by conventional short-read RNA-sequencing methods.

For families living with neurodegenerative disease, the hardest part is not always the diagnosis. It is the slow erosion that follows: memory fading, personality shifting, independence shrinking. It unfolds quietly. First, forgotten appointments. Then repeated questions. Then moments when a familiar face no longer feels familiar. The illness does not isolate itself to one body. It rearranges the lives around it.

As for side effects, the companies reported that little had changed from previous analyses; adverse events were similar between the two groups. The top side effects linked to the vaccine were fatigue, injection site pain, and chills. The results "highlight the potential of a prolonged benefit" of the vaccine combined with Keytruda in patients with high-risk melanoma," Kyle Holen, a senior vice president at Moderna, said. They also "illustrate mRNA's potential in cancer care," he said, noting that the company has eight more Phase 2 and Phase 3 trials going for mRNA vaccines against a variety of other cancers, including lung, bladder, and kidney cancers.

EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That's roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.

Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare genetic disorder primarily affecting boys, caused by a deficiency in the enzyme needed to break down sugar molecules. This harmful buildup in cells and tissues impacts multiple body systems, causing frequent infections, organ enlargement and developmental disabilities. Management involves supportive care and enzyme replacement therapy, as there is currently no cure,